Follow the people · Insider
Jay S. Stout
Jay S. Stout files insider transactions with the SEC as a chief technology officer of Immunovant (IMVT). We hold 7 disclosed purchases and sales filed since 5 April 2017, 3 of them in the last 90 days.
- Files forIMVT
- Disclosed buys and sells7 in all, 3 in the last 90 days
- Last disclosure24 July 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 17 April 2023 — 23 July 2026Chief Technology Officer · Immunovant (IMVT)34 Form 4 lines · source: SEC Form 4
- Filed 3 April 2017 — 24 April 2018SVP, Technical Operations · Versartis (VSAR)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
39 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 2,857 shares of ImmunovantSEC Form 424 July 2026Common Stock · traded 23 July 2026 · filed 24 July 2026
- ▼ sold on the open market 1,906 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 105 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 1,399 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 77 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 33,277 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 6,723 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 2,754 shares of ImmunovantSEC Form 424 April 2026Common Stock · traded 23 April 2026 · filed 24 April 2026
- ▼ sold on the open market 8,614 shares of ImmunovantSEC Form 410 April 2026Common Stock · traded 8 April 2026 · filed 10 April 2026
- ▼ sold on the open market 1,518 shares of ImmunovantSEC Form 410 April 2026Common Stock · traded 8 April 2026 · filed 10 April 2026
- was granted 66,937 shares of ImmunovantSEC Form 49 April 2026Common Stock · traded 7 April 2026 · filed 9 April 2026
- was granted 96,851 shares of Immunovant (a derivative holding)SEC Form 49 April 2026Stock Option (right to buy) · traded 7 April 2026 · filed 9 April 2026
- ▼ sold on the open market 1,977 shares of ImmunovantSEC Form 423 January 2026Common Stock · traded 21 January 2026 · filed 23 January 2026
- ▼ sold on the open market 1,977 shares of ImmunovantSEC Form 423 January 2026Common Stock · traded 21 January 2026 · filed 23 January 2026
- ▼ sold on the open market 1,148 shares of ImmunovantSEC Form 49 January 2026Common Stock · traded 7 January 2026 · filed 9 January 2026
- ▼ sold on the open market 55 shares of ImmunovantSEC Form 49 January 2026Common Stock · traded 7 January 2026 · filed 9 January 2026
- ▼ sold on the open market 1,148 shares of ImmunovantSEC Form 49 January 2026Common Stock · traded 7 January 2026 · filed 9 January 2026
- ▼ sold on the open market 55 shares of ImmunovantSEC Form 49 January 2026Common Stock · traded 7 January 2026 · filed 9 January 2026
- ▼ sold on the open market 2,520 shares of ImmunovantSEC Form 424 October 2025Common Stock · traded 22 October 2025 · filed 24 October 2025
- ▼ sold on the open market 1,585 shares of ImmunovantSEC Form 410 October 2025Common Stock · traded 8 October 2025 · filed 10 October 2025
- ▼ sold on the open market 2,805 shares of ImmunovantSEC Form 425 July 2025Common Stock · traded 23 July 2025 · filed 25 July 2025
- ▼ sold on the open market 1,519 shares of ImmunovantSEC Form 411 July 2025Common Stock · traded 9 July 2025 · filed 11 July 2025
- ▼ sold on the open market 1,925 shares of ImmunovantSEC Form 425 April 2025Common Stock · traded 23 April 2025 · filed 25 April 2025
- ▼ sold on the open market 5,004 shares of ImmunovantSEC Form 411 April 2025Common Stock · traded 9 April 2025 · filed 11 April 2025
- was granted 107,297 shares of Immunovant (a derivative holding)SEC Form 43 April 2025Stock Option (right to buy) · traded 1 April 2025 · filed 3 April 2025
- was granted 76,181 shares of ImmunovantSEC Form 43 April 2025Common Stock · traded 1 April 2025 · filed 3 April 2025
- ▼ sold on the open market 2,195 shares of ImmunovantSEC Form 424 January 2025Common Stock · traded 22 January 2025 · filed 24 January 2025
- ▼ sold on the open market 2,740 shares of ImmunovantSEC Form 425 October 2024Common Stock · traded 23 October 2024 · filed 25 October 2024
- ▼ sold on the open market 2,813 shares of ImmunovantSEC Form 426 July 2024Common Stock · traded 24 July 2024 · filed 26 July 2024
- ▼ sold on the open market 7,239 shares of ImmunovantSEC Form 426 April 2024Common Stock · traded 24 April 2024 · filed 26 April 2024
- was granted 68,723 shares of Immunovant (a derivative holding)SEC Form 44 April 2024Stock Option (right to buy) · traded 2 April 2024 · filed 4 April 2024
- was granted 54,978 shares of ImmunovantSEC Form 44 April 2024Common Stock · traded 2 April 2024 · filed 4 April 2024
- was granted 150,000 shares of Immunovant (a derivative holding)SEC Form 419 April 2023Stock Option (right to buy) · traded 17 April 2023 · filed 19 April 2023
- was granted 100,000 shares of ImmunovantSEC Form 419 April 2023Common Stock · traded 17 April 2023 · filed 19 April 2023
- ▼ sold on the open market 4,854 shares of VersartisSEC Form 425 April 2018Common Stock · traded 24 April 2018 · filed 25 April 2018
- was granted 74,500 shares of VersartisSEC Form 422 December 2017Common Stock · traded 20 December 2017 · filed 22 December 2017
- was granted 70,000 shares of VersartisSEC Form 410 October 2017Common Stock · traded 6 October 2017 · filed 10 October 2017
- was granted 45,000 shares of VersartisSEC Form 45 April 2017Common Stock · traded 3 April 2017 · filed 5 April 2017
- was granted 75,000 shares of Versartis (a derivative holding)SEC Form 45 April 2017Stock Option (Right to Buy) · traded 3 April 2017 · filed 5 April 2017
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.